PT - JOURNAL ARTICLE AU - Skowronski, Danuta M AU - Sekirov, Inna AU - Sabaiduc, Suzana AU - Zou, Macy AU - Morshed, Muhammad AU - Lawrence, David AU - Smolina, Kate AU - Ahmed, May A AU - Galanis, Eleni AU - Fraser, Mieke N AU - Singal, Mayank AU - Naus, Monika AU - Patrick, David M AU - Kaweski, Samantha E AU - Mill, Christopher AU - Reyes, Romina C AU - Kelly, Michael T AU - Levett, Paul N AU - Petric, Martin AU - Henry, Bonnie AU - Krajden, Mel TI - Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020 AID - 10.1101/2020.07.13.20153148 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.13.20153148 4099 - http://medrxiv.org/content/early/2020/07/15/2020.07.13.20153148.short 4100 - http://medrxiv.org/content/early/2020/07/15/2020.07.13.20153148.full AB - Background The province of British Columbia (BC) has been recognized for successful SARS-CoV-2 control, with surveillance data showing amongst the lowest case and death rates in Canada. We estimate sero-prevalence for two periods flanking the start (March) and end (May) of first-wave mitigation measures in BC.Methods Serial cross-sectional sampling was conducted using anonymized residual sera obtained from an outpatient laboratory network, including children and adults in the Greater Vancouver Area (population ∼3 million) where community attack rates were expected to be highest. Screening used two chemiluminescent immuno-assays for spike (S1) and nucleocapsid antibodies. Samples sero-positive on either screening assay were assessed by a third assay targeting the S1 receptor binding domain plus a neutralization assay. Age-standardized sero-prevalence estimates were based on dual-assay positivity. The May sero-prevalence estimate was extrapolated to the source population to assess surveillance under-ascertainment, quantified as the ratio of estimated infections versus reported cases.Results Serum collection dates spanned March 5-13 and May 15-27, 2020. In March, two of 869 specimens were dual-assay positive, with age-standardized sero-prevalence of 0.28% (95%CI=0.03-0.95). Neither specimen had detectable neutralizing antibodies. In May, four of 885 specimens were dual-assay positive, with age-standardized sero-prevalence of 0.55% (95%CI=0.15-1.37%). All four specimens had detectable neutralizing antibodies. We estimate ∼8 times more infections than reported cases.Conclusions Less than 1% of British Columbians had been infected with SARS-CoV-2 when first-wave mitigation measures were relaxed in May 2020. Our findings indicate successful suppression of community transmission in BC, but also substantial residual susceptibility. Further sero-survey snapshots are planned as the pandemic unfolds.Key points Cross-sectional sampling of anonymized residual sera at the start and end of first-wave mitigation measures in British Columbia, Canada shows SARS-CoV-2 sero-prevalence below 1% throughout the winter-spring 2020. Findings indicate successful suppression of community transmission but also substantial residual susceptibility.Competing Interest StatementDMS is Principal Investigator on grants from the Michael Smith Foundation for Health Research in support of this work. MK received grants/contracts paid to his institution from Roche, Hologic and Siemens. No other authors have conflicts of interest to disclose.Funding StatementFunding was provided in part by the Michael Smith Foundation for Health Research (Grant number 18934).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The sero-survey was authorized by the Provincial Health Officer and approved by the Clinical Research Ethics Board of the University of British Columbia (H20-00653).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData requests may be directed to the corresponding author and will be made available in accordance with the conditions of research ethics board and provincial privacy review.